France’s Bionyra Pharma launches with €143 million Series A to advance inflammatory disease biologics
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
France’s Bionyra Pharma launches with €143 million Series A to advance inflammatory disease biologics
Bionyra Pharma, a Paris and Boston-based clinical-stage biopharma company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch and its €143 million ($165 million) oversubscribed Series A financing The round is co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in this inaugural…
Bionyra launches with $165m, France's largest biotech Series A - European Biotechnology Magazine
With an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis. The post Bionyra launches with $165m, France’s largest…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
